CAR-T
Chimeric Antigen Receptor T-cell (CAR-T) therapy is a type of immunotherapy that uses the body’s own immune system to fight cancer. CAR-T cells are engineered to recognize and attack cancer cells, and they have been shown to be effective in treating a variety of different types of cancer, including leukemia, lymphoma, and myeloma.
CAR-T therapy is a complex and expensive treatment, but it has the potential to offer long-term remission for patients with cancer who have not responded to other treatments. In 2017, the FDA approved the first CAR-T therapy for the treatment of leukemia, and since then, several other CAR-T therapies have been approved for the treatment of different types of cancer.
Here’s a roundup of STAT coverage on a promising avenue of health and science research, including side effects and costs.
Most Read
STAT Plus: Vindicated. New J&J CAR-T myeloma data confirm strong efficacy, ease doubts raised by Chinese version
Hurdles abound in race to bring customized cancer treatments to masses
Federal panel approves first use of CRISPR in humans
STAT Plus: New data show Bluebird, Bristol CAR-T drug could be pioneering myeloma therapy. Competitors may be close behind
STAT Plus: Cellectis off-the-shelf CAR-T therapy grounded following patient’s toxic death
